| Literature DB >> 35529560 |
Cora Ballmann1, Markus Alexander Kölle2, Ines Bekavac-Günther3, Florian Wolf4, Florian Pargent5, Anne Barzel3, Alexandra Philipsen2, Jochen Gensichen1.
Abstract
Adult attention-deficit/hyperactivity disorder (ADHD) is common, but often undiagnosed. A valid and time-efficient screening tool for primary care is needed. Objective of this study is to evaluate the German version of the Adult ADHD Self-Report Scale for DSM-5 (ASRS-5) and its feasibility, acceptability, and reliability as a screening tool for adult ADHD in primary care. A multi-centered prospective, diagnostic study was performed. We recruited 262 patients in primary care practices and at an ADHD Outpatient Service of a department of psychiatry in Germany. Patients from 18 to 65 years with suspected or diagnosed ADHD were included by medical doctors, as well as non-ADHD patients as "negative controls." Participants filled in the ASRS-5 and a sociodemographic questionnaire. The Integrated Diagnosis of Adult ADHD, revised version (IDA-R) performed by trained interviewers was used for validation. Feasibility, acceptability, and credibility in primary care practices were examined through a semi-structured interview. The German version of the ASRS-5 showed comparable psychometric properties to the English original version (sensitivity 95.6% and specificity 72.3%). For factor structure, a parallel analysis suggested one latent dimension. Performing confirmatory factor analysis, the best fit was achieved for a general factor with one correlated error. Internal consistency results in Raykovs Omega = 0.86 and Cronbach's α = 0.88. The ASRS-5 was assessed positively in terms of feasibility, acceptability, and credibility by interviewed general practitioners. Potential problems were raised for "treatment options," "stigmatization," and "knowledge gaps." In conclusion, the German version of the ASRS-5 offers a promising tool to improve adult ADHD patients' diagnosis and healthcare.Entities:
Keywords: ADHD; ASRS-5; DSM-5; adult; primary care; screening
Year: 2022 PMID: 35529560 PMCID: PMC9075696 DOI: 10.3389/fpsyg.2022.858147
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
Clinical data.
| Total | GP setting | ADHD consultation hour | |
|---|---|---|---|
|
| |||
| Gender | 262 | 171 | 91 |
| Male | 118 (45) | 94 (55) | 49 (53.8) |
| Female | 143 (54.6) | 77 (45) | 41 (45.1) |
| Divers | 1 (0.4) | 0 | 1 (1.1) |
| Missing values | 0 | 0 | 0 |
| Age | Mean 39 (SD 13.6, 18–65) | Mean 41 (SD 13.9, 18–65) | Mean 36 (SD 12.3, 18–61) |
|
| 262 years | 171 years | 91 years |
| ≥ Highschool | 100 (38.2) | 77 (45.0) | 23 (25.3) |
| ≥ A Levels | 154 (58.8) | 90 (52.6) | 64 (70.3) |
| Others | 6 (2.3) | 2 (1.2) | 4 (4.4) |
| Missing values | 2 (0.8) | 2 (1.2) | 0 |
|
| |||
|
| 262 | 171 | 91 |
| No | 153 (58) | 117 (68.4) | 36 (39.6) |
| Yes | 96 (36) | 43 (24.6) | 54 (59.3) |
| Missing values | 13 (5) | 12 (7) | 1 (1.1) |
| Depression | 80 | 35 | 45 |
| Anxiety | 80 | 16 | 64 |
| Social phobia | 80 | 7 | 73 |
| Substance use disorder | 93 | 14 | 79 |
|
| 262 | 171 | 91 |
| Yes | 55 (21.0) | 22 (12.9) | 33 (36.3) |
| No | 202 (77.1) | 146 (85.4) | 56 (61.5) |
| Missing values | 5 (2.0) | 3 (1.8) | 2 (2.2) |
|
| |||
| Low (5–9 symptoms) | 64 | 21 | 43 |
| Moderate (10–11 symptoms) | 32 | 13 | 21 |
| High (12–14 symptoms) | 28 | 9 | 19 |
| Very high (15–18 symptoms) | 8 | 2 | 6 |
| Missing values | 0 | 0 | 0 |
|
| 113 | ||
| Inattentive | 64 | 13 | 51 |
| Hyperactive | 11 | 6 | 5 |
| Combined | 38 | 15 | 23 |
| Missing values | 0 | 0 | 0 |
SD, standard deviation.
Sensitivity and specificity.
| IDA-R pos | IDA-R neg | Total | |
|---|---|---|---|
| ASRS 5 pos | 108 | 41 | 149 |
| ASRS 5 neg | 5 | 107 | 112 |
| Total | 113 | 148 | 261 |
| Sensitivity | Specificity |